# Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid Tumors

> **NCT05508100** · PHASE1 · COMPLETED · sponsor: **Immune-Onc Therapeutics** · enrollment: 38 (actual)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **BIOLOGICAL:** IO-108
- **BIOLOGICAL:** IO-108 + pembrolizumab
- **BIOLOGICAL:** IO-108 + tislelizumab

## Key facts

- **NCT ID:** NCT05508100
- **Lead sponsor:** Immune-Onc Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-09
- **Primary completion:** 2024-04-30
- **Final completion:** 2024-04-30
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2024-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05508100

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05508100, "Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05508100. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*